Hindustan Bio Sciences Limited
Hindustan Bio Sciences Limited (HINDBIO.BO) Stock Competitors & Peer Comparison
See (HINDBIO.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HINDBIO.BO | ₹8.34 | +0.12% | 85.5M | 55.60 | ₹0.15 | N/A |
| MEDPLUS.BO | ₹835.45 | -0.09% | 100.3B | 48.40 | ₹17.26 | N/A |
| MEDPLUS.NS | ₹835.05 | -0.02% | 100.2B | 48.41 | ₹17.25 | N/A |
| GUJTHEM.BO | ₹318.80 | -4.75% | 34.7B | 72.62 | ₹4.39 | +0.21% |
| SHUKRAPHAR.BO | ₹37.45 | +4.26% | 16.4B | -187.25 | -₹0.20 | +0.05% |
| KPL.BO | ₹1,339.30 | -5.11% | 13.9B | 24.54 | ₹54.57 | N/A |
| SASTASUNDR.NS | ₹280.85 | -2.06% | 8.9B | 34.33 | ₹8.18 | N/A |
| SASTASUNDR.BO | ₹279.60 | -2.66% | 8.9B | 34.18 | ₹8.18 | N/A |
| FREDUN.BO | ₹1,646.60 | -1.23% | 7.8B | 23.56 | ₹69.90 | +0.04% |
| ANUHPHR.BO | ₹75.34 | +2.31% | 7.6B | 18.02 | ₹4.18 | +1.99% |
Stock Comparison
HINDBIO.BO vs MEDPLUS.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, MEDPLUS.BO has a market cap of 100.3B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while MEDPLUS.BO trades at ₹835.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas MEDPLUS.BO's P/E ratio is 48.40. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to MEDPLUS.BO's ROE of +0.12%. Regarding short-term risk, HINDBIO.BO is less volatile compared to MEDPLUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check MEDPLUS.BO's competition here
HINDBIO.BO vs MEDPLUS.NS Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, MEDPLUS.NS has a market cap of 100.2B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while MEDPLUS.NS trades at ₹835.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas MEDPLUS.NS's P/E ratio is 48.41. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, HINDBIO.BO is less volatile compared to MEDPLUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check MEDPLUS.NS's competition here
HINDBIO.BO vs GUJTHEM.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, GUJTHEM.BO has a market cap of 34.7B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while GUJTHEM.BO trades at ₹318.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas GUJTHEM.BO's P/E ratio is 72.62. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, HINDBIO.BO is less volatile compared to GUJTHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check GUJTHEM.BO's competition here
HINDBIO.BO vs SHUKRAPHAR.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SHUKRAPHAR.BO has a market cap of 16.4B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SHUKRAPHAR.BO trades at ₹37.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SHUKRAPHAR.BO's P/E ratio is -187.25. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SHUKRAPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SHUKRAPHAR.BO's competition here
HINDBIO.BO vs KPL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, KPL.BO has a market cap of 13.9B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while KPL.BO trades at ₹1,339.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas KPL.BO's P/E ratio is 24.54. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, HINDBIO.BO is less volatile compared to KPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check KPL.BO's competition here
HINDBIO.BO vs SASTASUNDR.NS Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SASTASUNDR.NS has a market cap of 8.9B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SASTASUNDR.NS trades at ₹280.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SASTASUNDR.NS's P/E ratio is 34.33. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SASTASUNDR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SASTASUNDR.NS's competition here
HINDBIO.BO vs SASTASUNDR.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SASTASUNDR.BO has a market cap of 8.9B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SASTASUNDR.BO trades at ₹279.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SASTASUNDR.BO's P/E ratio is 34.18. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SASTASUNDR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SASTASUNDR.BO's competition here
HINDBIO.BO vs FREDUN.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, FREDUN.BO has a market cap of 7.8B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while FREDUN.BO trades at ₹1,646.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas FREDUN.BO's P/E ratio is 23.56. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, HINDBIO.BO is less volatile compared to FREDUN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check FREDUN.BO's competition here
HINDBIO.BO vs ANUHPHR.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ANUHPHR.BO has a market cap of 7.6B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ANUHPHR.BO trades at ₹75.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ANUHPHR.BO's P/E ratio is 18.02. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, HINDBIO.BO is less volatile compared to ANUHPHR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check ANUHPHR.BO's competition here
HINDBIO.BO vs BPLPHARMA.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, BPLPHARMA.BO has a market cap of 7.5B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while BPLPHARMA.BO trades at ₹1,095.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas BPLPHARMA.BO's P/E ratio is -25.58. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, HINDBIO.BO is less volatile compared to BPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check BPLPHARMA.BO's competition here
HINDBIO.BO vs PRAVEG.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, PRAVEG.BO has a market cap of 6.8B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while PRAVEG.BO trades at ₹261.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas PRAVEG.BO's P/E ratio is -275.37. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, HINDBIO.BO is less volatile compared to PRAVEG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check PRAVEG.BO's competition here
HINDBIO.BO vs SGRL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SGRL.BO has a market cap of 6.7B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SGRL.BO trades at ₹518.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SGRL.BO's P/E ratio is 36.82. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SGRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SGRL.BO's competition here
HINDBIO.BO vs SUDARSHAN.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SUDARSHAN.BO has a market cap of 6.5B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SUDARSHAN.BO trades at ₹26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SUDARSHAN.BO's P/E ratio is 32.02. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SUDARSHAN.BO's ROE of +0.16%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SUDARSHAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SUDARSHAN.BO's competition here
HINDBIO.BO vs ALBERTDA.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ALBERTDA.BO's ROE of +0.02%. Regarding short-term risk, HINDBIO.BO is less volatile compared to ALBERTDA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check ALBERTDA.BO's competition here
HINDBIO.BO vs VIKRAMTH.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, VIKRAMTH.BO has a market cap of 4.8B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while VIKRAMTH.BO trades at ₹151.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas VIKRAMTH.BO's P/E ratio is 13.96. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, HINDBIO.BO is less volatile compared to VIKRAMTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check VIKRAMTH.BO's competition here
HINDBIO.BO vs JENBURPH.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, JENBURPH.BO has a market cap of 4.4B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while JENBURPH.BO trades at ₹996.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas JENBURPH.BO's P/E ratio is 13.56. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, HINDBIO.BO is less volatile compared to JENBURPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check JENBURPH.BO's competition here
HINDBIO.BO vs TLL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, TLL.BO has a market cap of 3.3B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while TLL.BO trades at ₹275.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas TLL.BO's P/E ratio is 22.20. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, HINDBIO.BO is more volatile compared to TLL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check TLL.BO's competition here
HINDBIO.BO vs GENNEX.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, GENNEX.BO has a market cap of 2.8B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while GENNEX.BO trades at ₹11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas GENNEX.BO's P/E ratio is 15.68. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, HINDBIO.BO is less volatile compared to GENNEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check GENNEX.BO's competition here
HINDBIO.BO vs ZENOTECH.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ZENOTECH.BO has a market cap of 2.8B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ZENOTECH.BO trades at ₹45.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ZENOTECH.BO's P/E ratio is 81.95. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, HINDBIO.BO is less volatile compared to ZENOTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check ZENOTECH.BO's competition here
HINDBIO.BO vs KERALAYUR.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, KERALAYUR.BO has a market cap of 2.6B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while KERALAYUR.BO trades at ₹218.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas KERALAYUR.BO's P/E ratio is -11.18. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, HINDBIO.BO is less volatile compared to KERALAYUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check KERALAYUR.BO's competition here
HINDBIO.BO vs BDH.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, BDH.BO has a market cap of 2.4B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while BDH.BO trades at ₹421.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas BDH.BO's P/E ratio is 23.31. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, HINDBIO.BO is less volatile compared to BDH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check BDH.BO's competition here
HINDBIO.BO vs SANJIVIN.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SANJIVIN.BO has a market cap of 2.4B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SANJIVIN.BO trades at ₹195.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SANJIVIN.BO's P/E ratio is 32.73. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SANJIVIN.BO's ROE of +0.22%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SANJIVIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SANJIVIN.BO's competition here
HINDBIO.BO vs SYSCHEM.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SYSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SYSCHEM.BO trades at ₹50.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SYSCHEM.BO's P/E ratio is 34.43. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SYSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SYSCHEM.BO's competition here
HINDBIO.BO vs TRANSCHEM.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, TRANSCHEM.BO has a market cap of 2.1B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while TRANSCHEM.BO trades at ₹174.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas TRANSCHEM.BO's P/E ratio is 72.82. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, HINDBIO.BO is less volatile compared to TRANSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check TRANSCHEM.BO's competition here
HINDBIO.BO vs AMBALALSA.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, AMBALALSA.BO has a market cap of 2B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while AMBALALSA.BO trades at ₹26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas AMBALALSA.BO's P/E ratio is 21.18. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, HINDBIO.BO is less volatile compared to AMBALALSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check AMBALALSA.BO's competition here
HINDBIO.BO vs OXYGENTAPH.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, OXYGENTAPH.BO has a market cap of 1.9B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while OXYGENTAPH.BO trades at ₹50.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas OXYGENTAPH.BO's P/E ratio is -10.67. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to OXYGENTAPH.BO's ROE of +0.65%. Regarding short-term risk, HINDBIO.BO is less volatile compared to OXYGENTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check OXYGENTAPH.BO's competition here
HINDBIO.BO vs AUROLAB.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, AUROLAB.BO has a market cap of 1.8B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while AUROLAB.BO trades at ₹293.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas AUROLAB.BO's P/E ratio is 56.62. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, HINDBIO.BO is less volatile compared to AUROLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check AUROLAB.BO's competition here
HINDBIO.BO vs NATCAPSUQ.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, NATCAPSUQ.BO has a market cap of 1.6B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while NATCAPSUQ.BO trades at ₹156.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas NATCAPSUQ.BO's P/E ratio is -13.59. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, HINDBIO.BO is less volatile compared to NATCAPSUQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check NATCAPSUQ.BO's competition here
HINDBIO.BO vs CORALAB.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, CORALAB.BO has a market cap of 1.5B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while CORALAB.BO trades at ₹430.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas CORALAB.BO's P/E ratio is 8.87. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, HINDBIO.BO is less volatile compared to CORALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check CORALAB.BO's competition here
HINDBIO.BO vs PARNAXLAB.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, PARNAXLAB.BO has a market cap of 1.5B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while PARNAXLAB.BO trades at ₹130.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas PARNAXLAB.BO's P/E ratio is 13.54. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, HINDBIO.BO is less volatile compared to PARNAXLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check PARNAXLAB.BO's competition here
HINDBIO.BO vs PANCHSHEEL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, PANCHSHEEL.BO has a market cap of 1.4B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while PANCHSHEEL.BO trades at ₹110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas PANCHSHEEL.BO's P/E ratio is 12.05. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, HINDBIO.BO is less volatile compared to PANCHSHEEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check PANCHSHEEL.BO's competition here
HINDBIO.BO vs KIMIABL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, KIMIABL.BO has a market cap of 1.4B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while KIMIABL.BO trades at ₹30.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to KIMIABL.BO's ROE of +1.10%. Regarding short-term risk, HINDBIO.BO is less volatile compared to KIMIABL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check KIMIABL.BO's competition here
HINDBIO.BO vs SMRUTHIORG.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SMRUTHIORG.BO has a market cap of 1.3B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SMRUTHIORG.BO trades at ₹112.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SMRUTHIORG.BO's P/E ratio is 27.63. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SMRUTHIORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SMRUTHIORG.BO's competition here
HINDBIO.BO vs LACTOSE.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, LACTOSE.BO has a market cap of 1.2B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while LACTOSE.BO trades at ₹96.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas LACTOSE.BO's P/E ratio is 41.57. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, HINDBIO.BO is less volatile compared to LACTOSE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check LACTOSE.BO's competition here
HINDBIO.BO vs TYCHE.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, TYCHE.BO has a market cap of 1.2B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while TYCHE.BO trades at ₹117.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas TYCHE.BO's P/E ratio is 12.33. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, HINDBIO.BO is less volatile compared to TYCHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check TYCHE.BO's competition here
HINDBIO.BO vs PHARMAID.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, PHARMAID.BO has a market cap of 1.2B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while PHARMAID.BO trades at ₹33.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas PHARMAID.BO's P/E ratio is -9.60. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to PHARMAID.BO's ROE of -0.24%. Regarding short-term risk, HINDBIO.BO is less volatile compared to PHARMAID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check PHARMAID.BO's competition here
HINDBIO.BO vs DENISCHEM.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, DENISCHEM.BO has a market cap of 1.1B. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while DENISCHEM.BO trades at ₹76.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas DENISCHEM.BO's P/E ratio is 14.77. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, HINDBIO.BO is less volatile compared to DENISCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check DENISCHEM.BO's competition here
HINDBIO.BO vs MERCURYLAB.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, MERCURYLAB.BO has a market cap of 961.9M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while MERCURYLAB.BO trades at ₹801.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas MERCURYLAB.BO's P/E ratio is 20.39. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, HINDBIO.BO is less volatile compared to MERCURYLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check MERCURYLAB.BO's competition here
HINDBIO.BO vs SOURCENTRL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SOURCENTRL.BO has a market cap of 853.9M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SOURCENTRL.BO trades at ₹132.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SOURCENTRL.BO's P/E ratio is 28.71. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SOURCENTRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SOURCENTRL.BO's competition here
HINDBIO.BO vs MAKERSL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, MAKERSL.BO has a market cap of 832.5M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while MAKERSL.BO trades at ₹141.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas MAKERSL.BO's P/E ratio is 68.50. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, HINDBIO.BO is less volatile compared to MAKERSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check MAKERSL.BO's competition here
HINDBIO.BO vs BIBCL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, BIBCL.BO has a market cap of 769.5M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while BIBCL.BO trades at ₹17.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas BIBCL.BO's P/E ratio is -4.80. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, HINDBIO.BO is less volatile compared to BIBCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check BIBCL.BO's competition here
HINDBIO.BO vs CONCORD.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, CONCORD.BO has a market cap of 765M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while CONCORD.BO trades at ₹76.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas CONCORD.BO's P/E ratio is 132.55. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, HINDBIO.BO is less volatile compared to CONCORD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check CONCORD.BO's competition here
HINDBIO.BO vs BACPHAR.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, BACPHAR.BO has a market cap of 717.7M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while BACPHAR.BO trades at ₹50.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas BACPHAR.BO's P/E ratio is 135.14. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, HINDBIO.BO is less volatile compared to BACPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check BACPHAR.BO's competition here
HINDBIO.BO vs SUNLOC.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SUNLOC.BO has a market cap of 707.1M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SUNLOC.BO trades at ₹67.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SUNLOC.BO's P/E ratio is 24.71. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SUNLOC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SUNLOC.BO's competition here
HINDBIO.BO vs PHRMASI.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, PHRMASI.BO has a market cap of 661.5M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while PHRMASI.BO trades at ₹96.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas PHRMASI.BO's P/E ratio is 3.73. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, HINDBIO.BO is more volatile compared to PHRMASI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check PHRMASI.BO's competition here
HINDBIO.BO vs GODAVARI.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, GODAVARI.BO has a market cap of 609.3M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while GODAVARI.BO trades at ₹80.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas GODAVARI.BO's P/E ratio is -88.91. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, HINDBIO.BO is less volatile compared to GODAVARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check GODAVARI.BO's competition here
HINDBIO.BO vs PANJON.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, PANJON.BO has a market cap of 497.8M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while PANJON.BO trades at ₹29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas PANJON.BO's P/E ratio is 116.00. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, HINDBIO.BO is less volatile compared to PANJON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check PANJON.BO's competition here
HINDBIO.BO vs VISTAPH.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, VISTAPH.BO has a market cap of 441.9M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while VISTAPH.BO trades at ₹7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas VISTAPH.BO's P/E ratio is -6.30. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, HINDBIO.BO is less volatile compared to VISTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check VISTAPH.BO's competition here
HINDBIO.BO vs SHELTER.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SHELTER.BO has a market cap of 404.8M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SHELTER.BO trades at ₹35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SHELTER.BO's P/E ratio is 6.47. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SHELTER.BO's ROE of +0.12%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SHELTER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SHELTER.BO's competition here
HINDBIO.BO vs VRL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, VRL.BO has a market cap of 400.3M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while VRL.BO trades at ₹125.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas VRL.BO's P/E ratio is 10.70. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to VRL.BO's ROE of +0.12%. Regarding short-term risk, HINDBIO.BO is less volatile compared to VRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check VRL.BO's competition here
HINDBIO.BO vs VEERHEALTH.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, VEERHEALTH.BO has a market cap of 392.6M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while VEERHEALTH.BO trades at ₹19.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas VEERHEALTH.BO's P/E ratio is 81.79. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, HINDBIO.BO is less volatile compared to VEERHEALTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check VEERHEALTH.BO's competition here
HINDBIO.BO vs SANDUPHQ.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SANDUPHQ.BO has a market cap of 351.2M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SANDUPHQ.BO trades at ₹36.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SANDUPHQ.BO's P/E ratio is 21.64. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, HINDBIO.BO is less volatile compared to SANDUPHQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check SANDUPHQ.BO's competition here
HINDBIO.BO vs ROOPAIND.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ROOPAIND.BO has a market cap of 337.7M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ROOPAIND.BO trades at ₹42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ROOPAIND.BO's P/E ratio is 17.53. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, HINDBIO.BO is less volatile compared to ROOPAIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check ROOPAIND.BO's competition here
HINDBIO.BO vs DECCAN.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, DECCAN.BO has a market cap of 314.4M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while DECCAN.BO trades at ₹13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas DECCAN.BO's P/E ratio is 23.54. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, HINDBIO.BO is less volatile compared to DECCAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check DECCAN.BO's competition here
HINDBIO.BO vs ANG.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ANG.BO has a market cap of 305M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ANG.BO trades at ₹23.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ANG.BO's P/E ratio is -2.50. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, HINDBIO.BO is less volatile compared to ANG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check ANG.BO's competition here
HINDBIO.BO vs MEDICAPQ.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, MEDICAPQ.BO has a market cap of 303M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while MEDICAPQ.BO trades at ₹24.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas MEDICAPQ.BO's P/E ratio is -5.38. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, HINDBIO.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check MEDICAPQ.BO's competition here
HINDBIO.BO vs GUJTERC.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, GUJTERC.BO has a market cap of 296.4M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while GUJTERC.BO trades at ₹39.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas GUJTERC.BO's P/E ratio is -21.36. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, HINDBIO.BO is less volatile compared to GUJTERC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check GUJTERC.BO's competition here
HINDBIO.BO vs CRSTCHM.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, CRSTCHM.BO has a market cap of 273M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while CRSTCHM.BO trades at ₹91.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas CRSTCHM.BO's P/E ratio is 13.48. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, HINDBIO.BO is less volatile compared to CRSTCHM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check CRSTCHM.BO's competition here
HINDBIO.BO vs TRIMURTHI.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to TRIMURTHI.BO's ROE of +0.04%. Regarding short-term risk, HINDBIO.BO is more volatile compared to TRIMURTHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check TRIMURTHI.BO's competition here
HINDBIO.BO vs ASRL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ASRL.BO has a market cap of 218.3M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ASRL.BO trades at ₹7.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ASRL.BO's P/E ratio is 12.85. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ASRL.BO's ROE of +0.01%. Regarding short-term risk, HINDBIO.BO is less volatile compared to ASRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check ASRL.BO's competition here
HINDBIO.BO vs ISHITADR.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ISHITADR.BO has a market cap of 206.3M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ISHITADR.BO trades at ₹69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ISHITADR.BO's P/E ratio is 23.23. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ISHITADR.BO's ROE of +0.08%. Regarding short-term risk, HINDBIO.BO is less volatile compared to ISHITADR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check ISHITADR.BO's competition here
HINDBIO.BO vs CHEMOPH.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to CHEMOPH.BO's ROE of -0.87%. Regarding short-term risk, HINDBIO.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check CHEMOPH.BO's competition here
HINDBIO.BO vs ZENITHHE.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ZENITHHE.BO has a market cap of 176.8M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ZENITHHE.BO trades at ₹3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ZENITHHE.BO's P/E ratio is -329.00. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, HINDBIO.BO is less volatile compared to ZENITHHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check ZENITHHE.BO's competition here
HINDBIO.BO vs NORRIS.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, NORRIS.BO has a market cap of 132.4M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while NORRIS.BO trades at ₹13.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to NORRIS.BO's ROE of +0.08%. Regarding short-term risk, HINDBIO.BO is less volatile compared to NORRIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check NORRIS.BO's competition here
HINDBIO.BO vs ZENLABS.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ZENLABS.BO has a market cap of 129.9M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ZENLABS.BO trades at ₹19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ZENLABS.BO's P/E ratio is -7.03. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ZENLABS.BO's ROE of -0.18%. Regarding short-term risk, HINDBIO.BO is less volatile compared to ZENLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check ZENLABS.BO's competition here
HINDBIO.BO vs EMMESSA.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, EMMESSA.BO has a market cap of 126.2M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while EMMESSA.BO trades at ₹25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas EMMESSA.BO's P/E ratio is 57.39. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, HINDBIO.BO is less volatile compared to EMMESSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check EMMESSA.BO's competition here
HINDBIO.BO vs CHCL.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, CHCL.BO has a market cap of 125.2M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while CHCL.BO trades at ₹5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, HINDBIO.BO is more volatile compared to CHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check CHCL.BO's competition here
HINDBIO.BO vs COLINZ.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, COLINZ.BO has a market cap of 119.7M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while COLINZ.BO trades at ₹47.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas COLINZ.BO's P/E ratio is 24.23. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, HINDBIO.BO is more volatile compared to COLINZ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check COLINZ.BO's competition here
HINDBIO.BO vs DESHRAK.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, DESHRAK.BO has a market cap of 113.7M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while DESHRAK.BO trades at ₹27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas DESHRAK.BO's P/E ratio is 30.90. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, HINDBIO.BO is more volatile compared to DESHRAK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check DESHRAK.BO's competition here
HINDBIO.BO vs TRINITYLEA.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, TRINITYLEA.BO has a market cap of 112.7M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while TRINITYLEA.BO trades at ₹14.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas TRINITYLEA.BO's P/E ratio is -474.67. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, HINDBIO.BO is less volatile compared to TRINITYLEA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check TRINITYLEA.BO's competition here
HINDBIO.BO vs PARMAX.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, PARMAX.BO has a market cap of 112.5M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while PARMAX.BO trades at ₹30.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas PARMAX.BO's P/E ratio is -3.86. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to PARMAX.BO's ROE of +2.05%. Regarding short-term risk, HINDBIO.BO is less volatile compared to PARMAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check PARMAX.BO's competition here
HINDBIO.BO vs SHAMROIN.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, SHAMROIN.BO has a market cap of 110.6M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while SHAMROIN.BO trades at ₹20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas SHAMROIN.BO's P/E ratio is -22.89. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to SHAMROIN.BO's ROE of -0.68%. Regarding short-term risk, HINDBIO.BO is more volatile compared to SHAMROIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check SHAMROIN.BO's competition here
HINDBIO.BO vs BERLDRG.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, BERLDRG.BO has a market cap of 109.5M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while BERLDRG.BO trades at ₹21.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas BERLDRG.BO's P/E ratio is 720.00. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, HINDBIO.BO is more volatile compared to BERLDRG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check BERLDRG.BO's competition here
HINDBIO.BO vs ADLINE.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, ADLINE.BO has a market cap of 82M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while ADLINE.BO trades at ₹14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, HINDBIO.BO is more volatile compared to ADLINE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check ADLINE.BO's competition here
HINDBIO.BO vs VIVANZA.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, VIVANZA.BO has a market cap of 81.6M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while VIVANZA.BO trades at ₹2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas VIVANZA.BO's P/E ratio is -25.50. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, HINDBIO.BO is less volatile compared to VIVANZA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check VIVANZA.BO's competition here
HINDBIO.BO vs EVOQ.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, EVOQ.BO has a market cap of 79.9M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while EVOQ.BO trades at ₹3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas EVOQ.BO's P/E ratio is 4.52. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, HINDBIO.BO is less volatile compared to EVOQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check EVOQ.BO's competition here
HINDBIO.BO vs DECIPHER.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, DECIPHER.BO has a market cap of 76.4M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while DECIPHER.BO trades at ₹7.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas DECIPHER.BO's P/E ratio is -0.94. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to DECIPHER.BO's ROE of -0.38%. Regarding short-term risk, HINDBIO.BO is less volatile compared to DECIPHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check DECIPHER.BO's competition here
HINDBIO.BO vs GANGAPHARM.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while GANGAPHARM.BO trades at ₹12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, HINDBIO.BO is more volatile compared to GANGAPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check GANGAPHARM.BO's competition here
HINDBIO.BO vs TIAANC.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, TIAANC.BO has a market cap of 66.2M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while TIAANC.BO trades at ₹6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas TIAANC.BO's P/E ratio is -64.50. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, HINDBIO.BO is less volatile compared to TIAANC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check TIAANC.BO's competition here
HINDBIO.BO vs KOBO.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, KOBO.BO has a market cap of 63.1M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while KOBO.BO trades at ₹2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas KOBO.BO's P/E ratio is -1.25. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, HINDBIO.BO is less volatile compared to KOBO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check KOBO.BO's competition here
HINDBIO.BO vs PATIDAR.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, PATIDAR.BO has a market cap of 52M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while PATIDAR.BO trades at ₹9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas PATIDAR.BO's P/E ratio is -19.29. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, HINDBIO.BO is more volatile compared to PATIDAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check PATIDAR.BO's competition here
HINDBIO.BO vs WELCURE.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, WELCURE.BO has a market cap of 38.2M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while WELCURE.BO trades at ₹0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas WELCURE.BO's P/E ratio is 1.17. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, HINDBIO.BO is less volatile compared to WELCURE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check WELCURE.BO's competition here
HINDBIO.BO vs TMTIND-B1.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, TMTIND-B1.BO has a market cap of 34.5M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while TMTIND-B1.BO trades at ₹6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas TMTIND-B1.BO's P/E ratio is -7.83. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, HINDBIO.BO is more volatile compared to TMTIND-B1.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HINDBIO.BO.Check TMTIND-B1.BO's competition here
HINDBIO.BO vs FABINO.BO Comparison February 2026
HINDBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HINDBIO.BO stands at 85.5M. In comparison, FABINO.BO has a market cap of 27.5M. Regarding current trading prices, HINDBIO.BO is priced at ₹8.34, while FABINO.BO trades at ₹13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HINDBIO.BO currently has a P/E ratio of 55.60, whereas FABINO.BO's P/E ratio is -17.95. In terms of profitability, HINDBIO.BO's ROE is +0.17%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, HINDBIO.BO is less volatile compared to FABINO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HINDBIO.BO.Check FABINO.BO's competition here